期刊文献+

尼洛替尼治疗进展期慢性粒细胞白血病的效果观察 被引量:2

下载PDF
导出
摘要 目的:分析用尼洛替尼治疗进展期慢性粒细胞白血病的临床疗效。方法:将2012年3月到2015年9月我院收治的20例进展期慢性粒细胞白血病患者作为研究对象。将这些患者随机分为对照组与研究组,每组各10例患者。对对照组患者进行化疗,为研究组患者使用尼洛替尼进行治疗,然后对比分析两组患者的临床疗效及发生不良反应的情况。结果:与对照组患者相比,研究组患者治疗的总有效率较高,差异有统计学意义(P<0.05)。与对照组患者相比,研究组患者在进行治疗期间其不良反应的发生率较低,差异有统计学意义(P<0.05)。结论:为进展期慢性粒细胞白血病患者使用尼洛替尼进行治疗可取得较好的效果,而且较少引起不良反应。
出处 《当代医药论丛》 2017年第8期99-100,共2页
  • 相关文献

参考文献8

二级参考文献92

  • 1O' BRIEN S G, GUILHOT F, LARSON R A, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia[J]. N Engl J Med, 2003,348 : 994-- 1004.
  • 2HOCHHAUS A, O' BRIEN S G, GUILHOT F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia[J]. Leukemia, 2009,23 : 1054-- 1061.
  • 3SHAH N P,NICOLL J M,NAGAR B,et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia[J]. Cancer Cell, 2002,2 .. 117 -- 125.
  • 4KANTARJIAN H M, GILES F, BHALLA K N, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results[J]. Blood,2011,117:1141--1145.
  • 5GILES F J,LARSON R A,KANTARJIAN H M,et al. Nilotinib in chronic myelogenous leukemia in blast crisis (CML-BC) patients with imatinib-resistance or -intolerance.. updated phase 2 results[J]. Haematolog- ica,2008,93(Suppl. 1) :abstract 0117.
  • 6HOCHHAUSA, GILES F, APPERLEY J, et al. Nilotinib in chronic myeloid leukemia in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study[J]. Haematologica, 2009,94 (Suppl. 2) .. abstract 0631.
  • 7LE COUTRE P, OTTMANN O G, GILES F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia[J]. Blood, 2008,111 ; 1834-- 1839.
  • 8KANTARJIAN H, GILES F, WUNDERI.E L, et al. Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome-Positive ALL[J]. N Engl J Med, 2006, 354:2542 2551.
  • 9KANTARJIAN H,GILES F, GATTERMANN N, et al. Nilotinib ( formerly AMN107 ), a highly selective BCR--ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance[J].Blood, 2007, 110: 3540- 3546.
  • 10LE COUTRE P, OTTMANN O G, GILES F, et al. Nilotinib (formerly AMN107), a highly selective BCR ABL tyrosine kinase inhibitor, is active in patients with imatinih-resistant or-intolerant accelerated-phase chronicmyelogenous leukemi[J]. Blood, 2008, 111:1835-1839.

共引文献42

同被引文献13

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部